NR 546 Advanced Psychopharmacology for the PMHNP
Midterm Exam Prep Document | 2026/2027 Edition | 200
Verified Questions - 189 Questions with Answers
NR 546 Midterm Exam 2026-189 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for the NR 546 Advanced
Psychopharmacology for the PMHNP midterm examination. It contains 200 verified questions and
answers, reflecting the actual exam structure and content. Designed to ensure a thorough understanding
of psychopharmacological principles, this resource is essential for PMHNP students aiming for a top
score. Each question is accompanied by a detailed rationale to reinforce learning and clinical
application.
Key Features:
Neurobiology and pathophysiology of psychiatric disorders
Mechanisms of action for all major psychotropic drug classes
FDA-approved indications and off-label uses
Side effect profiles, contraindications, and drug interactions
Patient education and monitoring parameters
Evidence-based prescribing guidelines and algorithms
Updates for 2026:
- Incorporate the latest DSM-5-TR diagnostic criteria
- Align with 2026-2027 AACN and NONPF competencies
- Include recent FDA approvals and black box warnings
- Update with current clinical practice guidelines from APA and CANMAT
- Revise to reflect the most recent exam blueprint and question distribution
Abstract:
The NR 546 Advanced Psychopharmacology for the PMHNP midterm examination assesses the student's ability to
integrate neurobiological principles with pharmacotherapeutic interventions across the lifespan. This preparation
document provides a comprehensive review of key topics including the pathophysiology of major psychiatric
disorders, pharmacokinetics and pharmacodynamics of psychotropic medications, and the clinical application of
evidence-based prescribing. Special emphasis is placed on safety, including side effect management, drug
interactions, and patient education. The content is structured to mirror the actual exam, with a focus on clinical
reasoning and decision-making. Each question is designed to challenge the student's understanding and
application of psychopharmacological principles in diverse patient scenarios. By engaging with these 200 verified
questions, students will enhance their readiness and confidence for the proctored exam, ensuring a graded A+
performance.
Keywords:
NR 546, PMHNP, Psychopharmacology, Midterm Exam, Verified Questions, Graded A+, Examplify, Advanced
Practice
Answer Format:
Each question is presented in the same format as the actual exam, with multiple-choice options. The correct answer
is clearly indicated, followed by a detailed rationale explaining why it is correct and why the other options are
incorrect. This approach reinforces understanding and aids in retention of key concepts.
Page 1
,Compliance Checklist:
200 questions covering all midterm exam topics
Answers verified by subject matter experts
Rationales provided for every question
Updated to reflect 2026-2027 curriculum standards
Organized by content area for efficient study
Suitable for self-assessment and exam simulation
Content Area Overview:
Content Area Questions Key Topics Weight
Neurobiology and 1-30 Neurotransmitters, receptor systems, brain 15%
Pathophysiology circuits, genetic factors
Antidepressants 31-60 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
antidepressants, ketamine
Antipsychotics 61-90 First-generation, second-generation, 15%
clozapine, long-acting injectables
Mood Stabilizers and 91-110 Lithium, valproate, lamotrigine, 10%
Anticonvulsants carbamazepine
Anxiolytics and Hypnotics 111-130 Benzodiazepines, buspirone, z-drugs, 10%
melatonin receptor agonists
Stimulants and ADHD 131-150 Methylphenidate, amphetamines, 10%
Medications non-stimulants (atomoxetine, guanfacine)
Special Populations and 151-170 Pregnancy, elderly, substance use disorders, 10%
Comorbidities medical comorbidities
Clinical Application and 171-200 Case studies, drug interactions, monitoring, 15%
Prescribing patient education
Page 2
,Q1. Which receptor profile most accurately distinguishes the pharmacologic action of
aripiprazole from that of cariprazine when considering their potential for inducing
akathisia?
A. Aripiprazole has higher 5-HT2A occupancy, while cariprazine has higher H1
occupancy.
B. Cariprazine exhibits functional selectivity at D3 receptors, whereas aripiprazole is a
D2 partial agonist with minimal D3 affinity.
C. Aripiprazole is a full D2 agonist, while cariprazine is a D2 antagonist.
D. Both are D2 partial agonists, but cariprazine has lower 5-HT1A affinity, increasing
motor side effects.
Correct Answer: B. Cariprazine exhibits functional selectivity at D3 receptors,
whereas aripiprazole is a D2 partial agonist with minimal D3 affinity.
Rationale: Cariprazine is distinguished by its high affinity and functional selectivity at D3
receptors, which contributes to its unique efficacy in negative symptoms and its distinct
side effect profile. Aripiprazole is a D2 partial agonist with comparatively lower D3
affinity. The other options misrepresent the receptor profiles: aripiprazole is not a full
agonist, and cariprazine's 5-HT1A affinity is actually high, not low.
Why Wrong:
A - Aripiprazole has higher D2 and 5-HT1A affinity, not 5-HT2A, and cariprazine has
lower H1 affinity.
C - Both are partial agonists at D2; neither is a full agonist or antagonist.
D - Cariprazine has higher 5-HT1A affinity, not lower, and both are D2 partial
agonists.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Q2. A patient on fluoxetine for 6 weeks develops hyponatremia. Which mechanism
best explains this adverse effect, and what is the most appropriate initial
management?
A. Serotonin-induced SIADH; discontinue fluoxetine and restrict fluids.
B. Dopamine blockade leading to nephrogenic diabetes insipidus; add desmopressin.
C. Enhanced ADH release due to 5-HT2C antagonism; continue fluoxetine and add
sodium tablets.
D. Direct tubular toxicity; switch to an SNRI and monitor serum sodium.
Correct Answer: A. Serotonin-induced SIADH; discontinue fluoxetine and restrict
fluids.
Rationale: SSRIs can cause SIADH by increasing serotonin-mediated ADH release,
leading to water retention and dilutional hyponatremia. The mainstay of treatment is
discontinuation of the offending agent and fluid restriction. The other options incorrectly
attribute the mechanism to dopamine blockade, 5-HT2C antagonism (which is not the
Page 3
, primary mediator), or direct tubular toxicity.
Why Wrong:
B - This describes diabetes insipidus, which presents with hypernatremia, not
hyponatremia.
C - 5-HT2C antagonism is not the mechanism; continuing the SSRI would worsen
hyponatremia.
D - SSRIs do not cause direct tubular toxicity; switching to an SNRI may not resolve
the issue.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 14.
Q3. Which cytochrome P450 isoenzyme is most responsible for the metabolism of
risperidone, and how does this influence drug interactions with paroxetine?
A. CYP3A4; paroxetine induces this enzyme, reducing risperidone levels.
B. CYP2D6; paroxetine inhibits this enzyme, increasing risperidone levels.
C. CYP1A2; paroxetine inhibits this enzyme, increasing risperidone levels.
D. CYP2C19; paroxetine induces this enzyme, reducing risperidone levels.
Correct Answer: B. CYP2D6; paroxetine inhibits this enzyme, increasing risperidone
levels.
Rationale: Risperidone is primarily metabolized by CYP2D6. Paroxetine is a potent
CYP2D6 inhibitor, so coadministration leads to increased risperidone concentrations,
potentially causing extrapyramidal symptoms and QT prolongation. The other options
misidentify the enzyme and the direction of the interaction.
Why Wrong:
A - CYP3A4 is minor; paroxetine inhibits, not induces, CYP2D6.
C - CYP1A2 is not the primary enzyme; paroxetine does not significantly inhibit
CYP1A2.
D - CYP2C19 is minor; paroxetine inhibits, not induces, CYP2D6.
Reference: Sadock, B. J., Sadock, V. A., & Ruiz, P. (2015). Kaplan & Sadock's Synopsis of
Psychiatry, 11th Ed., Ch. 32.
Q4. Which combination of receptor affinities best explains the therapeutic and
adverse effect profile of olanzapine, including its high risk of metabolic syndrome?
A. High D2 antagonism, low 5-HT2A antagonism, high H1 antagonism
B. High 5-HT2A antagonism, high H1 antagonism, high M1 antagonism
C. Low H1 antagonism, low 5-HT2C antagonism, high D2 antagonism
D. High 5-HT1A agonism, low H1 antagonism, low M1 antagonism
Correct Answer: B. High 5-HT2A antagonism, high H1 antagonism, high M1
antagonism
Page 4
Midterm Exam Prep Document | 2026/2027 Edition | 200
Verified Questions - 189 Questions with Answers
NR 546 Midterm Exam 2026-189 QUESTIONS AND ANSWERS ALREADY GRADED A+. 100% Verified
Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document is meticulously curated for the NR 546 Advanced
Psychopharmacology for the PMHNP midterm examination. It contains 200 verified questions and
answers, reflecting the actual exam structure and content. Designed to ensure a thorough understanding
of psychopharmacological principles, this resource is essential for PMHNP students aiming for a top
score. Each question is accompanied by a detailed rationale to reinforce learning and clinical
application.
Key Features:
Neurobiology and pathophysiology of psychiatric disorders
Mechanisms of action for all major psychotropic drug classes
FDA-approved indications and off-label uses
Side effect profiles, contraindications, and drug interactions
Patient education and monitoring parameters
Evidence-based prescribing guidelines and algorithms
Updates for 2026:
- Incorporate the latest DSM-5-TR diagnostic criteria
- Align with 2026-2027 AACN and NONPF competencies
- Include recent FDA approvals and black box warnings
- Update with current clinical practice guidelines from APA and CANMAT
- Revise to reflect the most recent exam blueprint and question distribution
Abstract:
The NR 546 Advanced Psychopharmacology for the PMHNP midterm examination assesses the student's ability to
integrate neurobiological principles with pharmacotherapeutic interventions across the lifespan. This preparation
document provides a comprehensive review of key topics including the pathophysiology of major psychiatric
disorders, pharmacokinetics and pharmacodynamics of psychotropic medications, and the clinical application of
evidence-based prescribing. Special emphasis is placed on safety, including side effect management, drug
interactions, and patient education. The content is structured to mirror the actual exam, with a focus on clinical
reasoning and decision-making. Each question is designed to challenge the student's understanding and
application of psychopharmacological principles in diverse patient scenarios. By engaging with these 200 verified
questions, students will enhance their readiness and confidence for the proctored exam, ensuring a graded A+
performance.
Keywords:
NR 546, PMHNP, Psychopharmacology, Midterm Exam, Verified Questions, Graded A+, Examplify, Advanced
Practice
Answer Format:
Each question is presented in the same format as the actual exam, with multiple-choice options. The correct answer
is clearly indicated, followed by a detailed rationale explaining why it is correct and why the other options are
incorrect. This approach reinforces understanding and aids in retention of key concepts.
Page 1
,Compliance Checklist:
200 questions covering all midterm exam topics
Answers verified by subject matter experts
Rationales provided for every question
Updated to reflect 2026-2027 curriculum standards
Organized by content area for efficient study
Suitable for self-assessment and exam simulation
Content Area Overview:
Content Area Questions Key Topics Weight
Neurobiology and 1-30 Neurotransmitters, receptor systems, brain 15%
Pathophysiology circuits, genetic factors
Antidepressants 31-60 SSRIs, SNRIs, TCAs, MAOIs, atypical 15%
antidepressants, ketamine
Antipsychotics 61-90 First-generation, second-generation, 15%
clozapine, long-acting injectables
Mood Stabilizers and 91-110 Lithium, valproate, lamotrigine, 10%
Anticonvulsants carbamazepine
Anxiolytics and Hypnotics 111-130 Benzodiazepines, buspirone, z-drugs, 10%
melatonin receptor agonists
Stimulants and ADHD 131-150 Methylphenidate, amphetamines, 10%
Medications non-stimulants (atomoxetine, guanfacine)
Special Populations and 151-170 Pregnancy, elderly, substance use disorders, 10%
Comorbidities medical comorbidities
Clinical Application and 171-200 Case studies, drug interactions, monitoring, 15%
Prescribing patient education
Page 2
,Q1. Which receptor profile most accurately distinguishes the pharmacologic action of
aripiprazole from that of cariprazine when considering their potential for inducing
akathisia?
A. Aripiprazole has higher 5-HT2A occupancy, while cariprazine has higher H1
occupancy.
B. Cariprazine exhibits functional selectivity at D3 receptors, whereas aripiprazole is a
D2 partial agonist with minimal D3 affinity.
C. Aripiprazole is a full D2 agonist, while cariprazine is a D2 antagonist.
D. Both are D2 partial agonists, but cariprazine has lower 5-HT1A affinity, increasing
motor side effects.
Correct Answer: B. Cariprazine exhibits functional selectivity at D3 receptors,
whereas aripiprazole is a D2 partial agonist with minimal D3 affinity.
Rationale: Cariprazine is distinguished by its high affinity and functional selectivity at D3
receptors, which contributes to its unique efficacy in negative symptoms and its distinct
side effect profile. Aripiprazole is a D2 partial agonist with comparatively lower D3
affinity. The other options misrepresent the receptor profiles: aripiprazole is not a full
agonist, and cariprazine's 5-HT1A affinity is actually high, not low.
Why Wrong:
A - Aripiprazole has higher D2 and 5-HT1A affinity, not 5-HT2A, and cariprazine has
lower H1 affinity.
C - Both are partial agonists at D2; neither is a full agonist or antagonist.
D - Cariprazine has higher 5-HT1A affinity, not lower, and both are D2 partial
agonists.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Q2. A patient on fluoxetine for 6 weeks develops hyponatremia. Which mechanism
best explains this adverse effect, and what is the most appropriate initial
management?
A. Serotonin-induced SIADH; discontinue fluoxetine and restrict fluids.
B. Dopamine blockade leading to nephrogenic diabetes insipidus; add desmopressin.
C. Enhanced ADH release due to 5-HT2C antagonism; continue fluoxetine and add
sodium tablets.
D. Direct tubular toxicity; switch to an SNRI and monitor serum sodium.
Correct Answer: A. Serotonin-induced SIADH; discontinue fluoxetine and restrict
fluids.
Rationale: SSRIs can cause SIADH by increasing serotonin-mediated ADH release,
leading to water retention and dilutional hyponatremia. The mainstay of treatment is
discontinuation of the offending agent and fluid restriction. The other options incorrectly
attribute the mechanism to dopamine blockade, 5-HT2C antagonism (which is not the
Page 3
, primary mediator), or direct tubular toxicity.
Why Wrong:
B - This describes diabetes insipidus, which presents with hypernatremia, not
hyponatremia.
C - 5-HT2C antagonism is not the mechanism; continuing the SSRI would worsen
hyponatremia.
D - SSRIs do not cause direct tubular toxicity; switching to an SNRI may not resolve
the issue.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 14.
Q3. Which cytochrome P450 isoenzyme is most responsible for the metabolism of
risperidone, and how does this influence drug interactions with paroxetine?
A. CYP3A4; paroxetine induces this enzyme, reducing risperidone levels.
B. CYP2D6; paroxetine inhibits this enzyme, increasing risperidone levels.
C. CYP1A2; paroxetine inhibits this enzyme, increasing risperidone levels.
D. CYP2C19; paroxetine induces this enzyme, reducing risperidone levels.
Correct Answer: B. CYP2D6; paroxetine inhibits this enzyme, increasing risperidone
levels.
Rationale: Risperidone is primarily metabolized by CYP2D6. Paroxetine is a potent
CYP2D6 inhibitor, so coadministration leads to increased risperidone concentrations,
potentially causing extrapyramidal symptoms and QT prolongation. The other options
misidentify the enzyme and the direction of the interaction.
Why Wrong:
A - CYP3A4 is minor; paroxetine inhibits, not induces, CYP2D6.
C - CYP1A2 is not the primary enzyme; paroxetine does not significantly inhibit
CYP1A2.
D - CYP2C19 is minor; paroxetine inhibits, not induces, CYP2D6.
Reference: Sadock, B. J., Sadock, V. A., & Ruiz, P. (2015). Kaplan & Sadock's Synopsis of
Psychiatry, 11th Ed., Ch. 32.
Q4. Which combination of receptor affinities best explains the therapeutic and
adverse effect profile of olanzapine, including its high risk of metabolic syndrome?
A. High D2 antagonism, low 5-HT2A antagonism, high H1 antagonism
B. High 5-HT2A antagonism, high H1 antagonism, high M1 antagonism
C. Low H1 antagonism, low 5-HT2C antagonism, high D2 antagonism
D. High 5-HT1A agonism, low H1 antagonism, low M1 antagonism
Correct Answer: B. High 5-HT2A antagonism, high H1 antagonism, high M1
antagonism
Page 4
